Lifecore Biomedical sets November 4 record date for merger vote

Lifecore Biomedical, Inc. disclosed in an October 20, 2026 Form 8-K that its board of directors took action on October 16, 2026 to move forward with a previously announced merger. The company had entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. on September 27, 2026, and on October 16, 2026 the board set November 4, 2026 as the record date for a special meeting of stockholders to vote on adopting the merger agreement and approving the merger.¹

Shareholders who hold stock as of the record date will be eligible to receive notice of the special meeting and cast votes there, according to the filing.

Lifecore said it plans to make merger-related disclosures available to investors. Under the terms of the merger agreement, the company will file a preliminary proxy statement with the SEC for the special meeting and also intends to file a definitive proxy statement.¹ Copies of the proxy statement and related filings will be posted on the SEC's website once available, and investors can also access them through the investor relations section of Lifecore's website or by phone.¹

The filing notes that Lifecore's directors and executive officers could be considered part of the group soliciting stockholder proxies for the merger vote. Details on those directors and officers, including their holdings and interests, appear in the company's definitive proxy statement for its 2026 Annual Meeting of Stockholders, filed with the SEC on April 24, 2026, along with any later ownership changes reported on subsequent SEC forms.¹

The report was signed by Chief Financial Officer Ryan D. Lake.